Jerome Ritz

Jerome Ritz

Auto-generated profile, based on publicly available information

Jerome Ritz

Dana-Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts, United States

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JKJohn Koreth
John Koreth
KMKen-Ichi Matsuoka
Ken-Ichi Matsuoka
HKHaesook T. Kim
Haesook T. Kim
SMSean M. McDonough
Sean M. McDonough
BBBhavjot Bindra
Bhavjot Bindra
RSRobert J. Soiffer
Robert J. Soiffer
Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×106, 1×106, or 3×106 IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×106 IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P<0.001), without affecting CD4+ conventional T (Tcon) cells. The Treg:Tcon ratio increased to a median of more than five times the baseline value (P<0.001). The Treg cell count and Treg:Tcon ratio remained elevated at 8 weeks (P<0.001 for both comparisons with baseline values), then declined when the patients were not receiving interleukin-2. The increased numbers of Treg cells expressed the transcription factor forkhead box P3 (FOXP3) and could inhibit autologous Tcon cells. Immunologic and clinical responses were sustained in patients who received interleukin-2 for an extended period, permitting the glucocorticoid dose to be tapered by a mean of 60% (range, 25 to 100). Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy. Administration was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GVHD in a substantial proportion of patients. (Funded by a Dana–Farber Dunkin' Donuts Rising Star award and others; ClinicalTrials.gov number, NCT00529035.)

1 September 1985 in Cell
Verified
Journal Article
Closed access
MTMasahide Takahashi
Masahide Takahashi
JRJerome Ritz
Jerome Ritz
GCGeoffrey M. Cooper
Geoffrey M. Cooper

1 September 2006 in Blood
Verified
Journal Article
Open access
PDF file
EZEmmanuel Zorn
Emmanuel Zorn
ENErik A. Nelson
Erik A. Nelson
MMMehrdad Mohseni
Mehrdad Mohseni
FPFabrice Porcheray
Fabrice Porcheray
HKHaesook Kim
Haesook Kim
JRJerome Ritz
Jerome Ritz
IL-2 plays a critical role in the maintenance of CD4+CD25+ FOXP3+ regulatory T cells (Tregs) in vivo. We examined the effects of IL-2 signaling in human Tregs. In vitro, IL-2 selectively up-regulated the expression of FOXP3 in purified CD4+CD25+ T cells but not in CD4+CD25- cells. This regulation involved the binding of STAT3 and STAT5 proteins to a highly conserved STAT-binding site located in the first intron of the FOXP3 gene. We also examined the effects of low-dose IL-2 treatment in 12 patients with metastatic cancer and 9 patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. Overall, IL-2 treatment resulted in a 1.9 median fold increase in the frequency of CD4+CD25+ cells in peripheral blood as well as a 9.7 median fold increase in FOXP3 expression in CD3+ T cells. CD56+CD3- natural killer (NK) cells also expanded during IL-2 therapy but did not express FOXP3. In vitro treatment of NK cells with 5-aza-2′-deoxycytidine restored the IL-2 signaling pathway leading to FOXP3 expression, suggesting that this gene was constitutively repressed by DNA methylation in these cells. Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo.

21 January 2011 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
CNCésar Nombela-Arrieta
César Nombela-Arrieta
JRJerome Ritz
Jerome Ritz
LSLeslie E. Silberstein
Leslie E. Silberstein

1 February 1980 in Nature
Verified
Journal Article
Closed access
PDF file
JRJerome Ritz
Jerome Ritz
JPJohn M. Pesando
John M. Pesando
JNJean Notis-McConarty
Jean Notis-McConarty
HLHerbert Lazarus
Herbert Lazarus
SSStuart F. Schlossman
Stuart F. Schlossman

1 February 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KCKenneth R. Cooke
Kenneth R. Cooke
LLLeo Luznik
Leo Luznik
SSStefanie Sarantopoulos
Stefanie Sarantopoulos
FHFrances T. Hakim
Frances T. Hakim
MJMadan Jagasia
Madan Jagasia
BBBruce R. Blazar
Bruce R. Blazar
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disability in allogeneic hematopoietic cell transplantation recipients and a major obstacle to improving outcomes. The biology of chronic GVHD remains enigmatic, but understanding the underpinnings of the immunologic mechanisms responsible for the initiation and progression of disease is fundamental to developing effective prevention and treatment strategies. The goals of this task force review are as follows: This document is intended as a review of our understanding of chronic GVHD biology and therapies resulting from preclinical studies, and as a platform for developing innovative clinical strategies to prevent and treat chronic GVHD.